233 related articles for article (PubMed ID: 33161771)
1. Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis.
Endo Y; Fukui S; Umekita K; Suzuki T; Miyamoto J; Morimoto S; Shimizu T; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Okada A; Fujikawa K; Mizokami A; Matsuoka N; Aramaki T; Ueki Y; Eguchi K; Kariya Y; Hashiba Y; Hidaka T; Okayama A; Kawakami A; Nakamura H
Mod Rheumatol; 2021 Sep; 31(5):972-978. PubMed ID: 33161771
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
Suzuki T; Fukui S; Umekita K; Miyamoto J; Umeda M; Nishino A; Okada A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Fujikawa K; Aramaki T; Mizokami A; Matsuoka N; Ueki Y; Eguchi K; Sato S; Hidaka T; Origuchi T; Okayama A; Kawakami A; Nakamura H
Arthritis Rheumatol; 2018 Jul; 70(7):1014-1021. PubMed ID: 29471588
[TBL] [Abstract][Full Text] [Related]
3. Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.
Umekita K; Hidaka T; Miyauchi S; Ueno S; Kubo K; Takajo I; Hashiba Y; Kai Y; Nagatomo Y; Okayama A
Arthritis Care Res (Hoboken); 2014 May; 66(5):788-92. PubMed ID: 24127184
[TBL] [Abstract][Full Text] [Related]
4. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy.
Fukui S; Nakamura H; Takahashi Y; Iwamoto N; Hasegawa H; Yanagihara K; Nakamura T; Okayama A; Kawakami A
BMC Immunol; 2017 Feb; 18(1):7. PubMed ID: 28158970
[TBL] [Abstract][Full Text] [Related]
6. Effect of HTLV-1 Infection on the Clinical Course of Patients with Rheumatoid Arthritis.
Umekita K
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891440
[TBL] [Abstract][Full Text] [Related]
7. Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy.
Iwao C; Umekita K; Miyauchi S; Kimura M; Rikitake Y; Iwao K; Rikitake M; Aizawa A; Kawaguchi T; Kariya Y; Matsuda M; Takajo I; Shiomi K; Okayama A
Intern Med; 2020 Aug; 59(15):1891-1897. PubMed ID: 32321893
[TBL] [Abstract][Full Text] [Related]
8. HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional Observation Study.
Umekita K; Hashikura Y; Takaki A; Kimura M; Kawano K; Iwao C; Miyauchi S; Kawaguchi T; Matsuda M; Hashiba Y; Hidaka T
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851682
[TBL] [Abstract][Full Text] [Related]
9. Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.
Terada Y; Kamoi K; Ohno-Matsui K; Miyata K; Yamano C; Coler-Reilly A; Yamano Y
Medicine (Baltimore); 2017 Feb; 96(6):e6021. PubMed ID: 28178142
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
12. Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis.
Nozuma S; Kubota R; Jacobson S
J Neurovirol; 2020 Oct; 26(5):652-663. PubMed ID: 32705480
[TBL] [Abstract][Full Text] [Related]
13.
Hashiba Y; Umekita K; Minami H; Kawano A; Nagayasu E; Maruyama H; Hidaka T; Okayama A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):16-21. PubMed ID: 32772699
[TBL] [Abstract][Full Text] [Related]
14. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
15. HTLV-1 Infection and Rheumatic Diseases.
Umekita K; Okayama A
Front Microbiol; 2020; 11():152. PubMed ID: 32117170
[TBL] [Abstract][Full Text] [Related]
16. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
17. Human T-lymphotropic virus 1 (HTLV-1)-associated lichenoid dermatitis induced by CD8+ T cells in HTLV-1 carrier, HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia/lymphoma.
Tokura Y; Ito T; Kawakami C; Sugita K; Kasuya A; Tatsuno K; Sawada Y; Nakamura M; Shimauchi T
J Dermatol; 2015 Oct; 42(10):967-74. PubMed ID: 26077665
[TBL] [Abstract][Full Text] [Related]
18. Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.
Nascimento MC; Primo J; Bittencourt A; Siqueira I; de Fátima Oliveira M; Meyer R; Schriefer A; Santos SB; Carvalho EM
Clin Exp Immunol; 2009 Jun; 156(3):455-62. PubMed ID: 19438598
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
[TBL] [Abstract][Full Text] [Related]
20. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
